Access the full text.
Sign up today, get DeepDyve free for 14 days.
Qingding Wang, Xiao-fu Wang, Ambrosio Hernandez, M. Hellmich, Z. Gatalica, B. Evers (2002)
Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells*The Journal of Biological Chemistry, 277
C. Mitsiades, N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S. Treon, Nikhil Munshi, P. Richardson, K. Anderson (2002)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsOncogene, 21
B. Jansen, V. Wacheck, E. Heere‐Ress, H. Schlagbauer‐Wadl, Christoph Hoeller, T. Lucas, M. Hoermann, U. Hollenstein, Klaus Wolff, H. Pehamberger (2000)
Chemosensitisation of malignant melanoma by BCL2 antisense therapyThe Lancet, 356
Markus Müschen, U. Warskulat, M. Beckmann (2000)
Defining CD95 as a tumor suppressor geneJournal of Molecular Medicine, 78
Nesrin Özören, Kunhong Kim, T. Burns, D. Dicker, A. Moscioni, W. El-Deiry (2000)
The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.Cancer research, 60 22
A. Younes, J. Vose, A. Zelenetz, Mitchell Smith, H. Burris, S. Ansell, J. Klein, E. Kumm, M. Czuczman (2005)
Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).Blood, 106
B. Paterson, B. Roberts, E. Kuff (1977)
Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation.Proceedings of the National Academy of Sciences of the United States of America, 74 10
I. Tamm, S. Richter, Doreen Oltersdorf, U. Creutzig, J. Harbott, Frank Scholz, L. Karawajew, W. Ludwig, C. Wuchter (2004)
High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid LeukemiaClinical Cancer Research, 10
D. Antwerp, Seamus Martin, I. Verma, D. Green (1998)
Inhibition of TNF-induced apoptosis by NF-κBTrends in Cell Biology, 8
G. Marcucci, J. Byrd, G. Dai, M. Klisovic, P. Kourlas, D. Young, S. Cataland, D. Fisher, D. Lucas, K. Chan, P. Porcu, Zhong Lin, Sherif Farag, S. Frankel, J. Zwiebel, E. Kraut, S. Balcerzak, C. Bloomfield, M. Grever, M. Caligiuri (2003)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.Blood, 101 2
T. Burns, W. El-Deiry (2001)
Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach.The Journal of biological chemistry, 276 41
E. Schlette, L. Medeiros, A. Goy, R. Lai, G. Rassidakis (2004)
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
M. Morris, W. Tong, C. Cordon-Cardo, M. Drobnjak, W. Kelly, S. Slovin, K. Terry, Karen Siedlecki, P. Swanson, M. Rafi, R. DiPaola, N. Rosen, H. Scher (2002)
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 3
F. Kischkel, D. Lawrence, A. Tinel, Heidi Leblanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, A. Ashkenazi (2001)
Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8*The Journal of Biological Chemistry, 276
T. Gura (1997)
How TRAIL Kills Cancer Cells, But Not Normal CellsScience, 277
Baoxiang Guan, P. Yue, G. Clayman, Shi-Yong Sun (2001)
Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated geneJournal of Cellular Physiology, 188
K. Ryan, A. Phillips, K. Vousden (2001)
Regulation and function of the p53 tumor suppressor protein.Current opinion in cell biology, 13 3
R. Hofer-Warbinek, J. Schmid, C. Stehlik, B. Binder, J. Lipp, R. Martin (2000)
Activation of NF-κB by XIAP, the X Chromosome-linked Inhibitor of Apoptosis, in Endothelial Cells Involves TAK1*The Journal of Biological Chemistry, 275
H. Miayake, A. Tolcher, Martin Gleave (2000)
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.Journal of the National Cancer Institute, 92 1
J. Waters, A. Webb, D. Cunningham, P. Clarke, F. Raynaud, F. Stefano, F. Cotter (2000)
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 9
Jürgen Held, K. Schulze-Osthoff (2001)
Potential and caveats of TRAIL in cancer therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 4 4
A. Islam, H. Kageyama, N. Takada, Takemasa Kawamato, H. Takayasu, E. Isogai, M. Ohira, K. Hashizume, Hirofumi Kobayashi, Y. Kaneko, A. Nakagawara (2000)
High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 19
R. Feinman, D. Siegel, James Berenson (2004)
Regulation of NF-kB in multiple myeloma: therapeutic implications.Clinical advances in hematology & oncology : H&O, 2 3
N. Rampino, H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, John Reed, M. Perucho (1997)
Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator PhenotypeScience, 275
S. Fukuda, L. Pelus (2001)
Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.Blood, 98 7
J. Bodmer, N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, J. Tschopp (2000)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8Nature Cell Biology, 2
P. Rogers, P. Beale, M. Al-Moundhri, F. Boxall, Lisa Patterson, M. Valenti, F. Raynaud, S. Hobbs, S. Johnston, L. Kelland (2002)
Overexpression of BclXL in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivity in vitro versus in vivoInternational Journal of Cancer, 97
A. Mirza, Marnie McGuirk, Tish Hockenberry, Qun Wu, H. Ashar, Stuart Black, S. Wen, Luquan Wang, P. Kirschmeier, W. Bishop, L. Nielsen, C. Pickett, Suxing Liu (2002)
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathwayOncogene, 21
John Reed (2001)
The Survivin saga goes in vivo.The Journal of clinical investigation, 108 7
D Hanahan, RA Weinberg (2000)
The hallmarks of cancerCell, 100
S. Hotte, H. Hirte, E. Chen, L. Lê, A. Corey, M. Maclean, A. Iacobucci, N. Fox, A. Oza (2005)
HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trialJournal of Clinical Oncology, 23
J. Tran, Zubin Master, Joanne Yu, J. Rak, D. Dumont, R. Kerbel (2002)
A role for survivin in chemoresistance of endothelial cells mediated by VEGFProceedings of the National Academy of Sciences of the United States of America, 99
S. Shariat, Y. Lotan, H. Saboorian, S. Khoddami, C. Roehrborn, K. Slawin, R. Ashfaq (2004)
Survivin expression is associated with features of biologically aggressive prostate carcinomaCancer, 100
Roy Herbst, D. Mendolson, S. Ebbinghaus, Michael Gordon, Peter O'Dwyer, G. Lieberman, J. Ing, R. Kurzrock, William Novotny, Gail Eckhardt (2006)
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
D. Grossman, J. McNiff, F. Li, D. Altieri (1999)
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.The Journal of investigative dermatology, 113 6
Fengzhi Li, G. Ambrosini, E. Chu, J. Plescia, S. Tognin, P. Marchisio, D. Altieri (1998)
Control of apoptosis and mitotic spindle checkpoint by survivinNature, 396
B. Gliniak, Tiep Le (1999)
Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.Cancer research, 59 24
A. Eggert, M. Grotzer, T. Zuzak, B. Wiewrodt, R. Ho, N. Ikegaki, G. Brodeur (2001)
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.Cancer research, 61 4
L. Altucci, A. Rossin, W. Raffelsberger, A. Reitmair, C. Chomienne, H. Gronemeyer (2001)
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAILNature Medicine, 7
P. Krammer (1999)
CD95(APO-1/Fas)-mediated apoptosis: live and let die.Advances in immunology, 71
T. Ohmori, E. Podack, K. Nishio, M. Takahashi, Y. Miyahara, Y. Takeda, N. Kubota, Y. Funayama, H. Ogasawara, T. Ohira (1993)
Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.Biochemical and biophysical research communications, 192 1
T. McDonnell, P. Troncoso, S. Brisbay, C. Logothetis, Leland Chung, J. Hsieh, S. Tu, M. Campbell (1992)
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.Cancer research, 52 24
T. Kuwana, L. Bouchier-Hayes, J. Chipuk, Christine Bonzon, B. Sullivan, D. Green, D. Newmeyer (2005)
BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.Molecular cell, 17 4
N. Kyprianou, E. King, David Bradbury, J. Rhee (1997)
bcl‐2 over‐expression delays radiation‐induced apoptosis without affecting the clonogenic survival of human prostate cancer cellsInternational Journal of Cancer, 70
John Reed (1998)
Dysregulation of apoptosis in cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
X. Dolcet, D. Llobet, J. Pallarés, X. Matías-Guiu (2005)
NF-kB in development and progression of human cancerVirchows Archiv, 446
K. Wagner, I. Engels, Q. Deveraux (2004)
Caspase-2 Can Function Upstream of Bid Cleavage in the TRAIL Apoptosis Pathway*Journal of Biological Chemistry, 279
Y. Soung, J. Lee, S. Kim, Jin Jang, Yong-Gyu Park, W. Park, S. Nam, Jung Lee, N. Yoo, S. Lee (2005)
CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas.Cancer research, 65 3
C. Adida, P. Crotty, J. Mcgrath, D. Berrebi, J. Diebold, D. Altieri (1998)
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.The American journal of pathology, 152 1
William Hoffman, S. Biade, J. Zilfou, Jiandong Chen, M. Murphy (2002)
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53*The Journal of Biological Chemistry, 277
S. Datta, A. Brunet, M. Greenberg (1999)
Cellular survival: a play in three Akts.Genes & development, 13 22
A. Nebreda, A. Gavin (1999)
Cell Survival Demands Some RskScience, 286
Min Shin, Hong-Sug Kim, S. Lee, W. Park, S. Kim, J. Park, Jong Lee, Sang Lee, Shi Lee, Sang Jung, Ji Han, Hyang Kim, Jung Lee, N. Yoo (2001)
Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.Cancer research, 61 13
B. Vogelstein, D. Lane, A. Levine (2000)
Surfing the p53 networkNature, 408
L. Bin, Xiaoyan Li, Liang-Guo Xu, H. Shu (2002)
The short splice form of Casper/c‐FLIP is a major cellular inhibitor of TRAIL‐induced apoptosisFEBS Letters, 510
M. Winston (1996)
Bee Work: The Wisdom of the Hive.Science, 272
Keitarou Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, N. Tanigawa (2000)
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 1
S. Kondo, Y. Shinomura, Y. Miyazaki, T. Kiyohara, S. Tsutsui, S. Kitamura, Y. Nagasawa, M. Nakahara, S. Kanayama, Y. Matsuzawa (2000)
Mutations of the bak gene in human gastric and colorectal cancers.Cancer research, 60 16
C. Weldon, Amanda Parker, Daniel Patten, S. Elliott, Yan Tang, Daniel Frigo, C. Dugan, E. Coakley, Nancy Butler, J. Clayton, J. Alam, T. Curiel, B. Beckman, B. Jaffe, M. Burow (2004)
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.International journal of oncology, 24 6
N. Ozören, W. El-Deiry (2002)
Defining characteristics of Types I and II apoptotic cells in response to TRAIL.Neoplasia, 4 6
A. Verhagen, P. Ekert, M. Pakusch, J. Silke, L. Connolly, G. Reid, R. Moritz, R. Simpson, D. Vaux (2000)
Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP ProteinsCell, 102
J. Mcgreivy, J. Marshall, B. Cheson, J. Hwang, S. Malik, P. Lebowitz, J. Mangipudy, C. Soho, J. Viallet (2005)
Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitorJournal of Clinical Oncology, 23
M. Kappler, M. Bache, F. Bartel, M. Kotzsch, Matti Panian, P. Würl, K. Blümke, H. Schmidt, A. Meye, H. Taubert (2004)
Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53Cancer Gene Therapy, 11
A. Kuang, G. Diehl, Jianke Zhang, A. Winoto (2000)
FADD Is Required for DR4- and DR5-mediated ApoptosisThe Journal of Biological Chemistry, 275
D. Altieri (2003)
Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 22
R. Pitti, S. Marsters, S. Ruppert, C. Donahue, A. Moore, A. Ashkenazi (1996)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*The Journal of Biological Chemistry, 271
R. Loomis, Rocco Carbone, M. Reiss, J. Lacy (2003)
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 5
Y. Gazitt (1999)
TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cellsLeukemia, 13
M. Monzó, R. Rosell, E. Felip, J. Astudillo, J. Sánchez, J. Maestre, Cristina Martín, A. Font, A. Barnadas, A. Abad (1999)
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
L. Vassilev, B. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, Norman Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. Liu (2004)
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 303
B. Conradt, H. Horvitz (1998)
The C. elegans Protein EGL-1 Is Required for Programmed Cell Death and Interacts with the Bcl-2–like Protein CED-9Cell, 93
A. Giodini, M. Kallio, N. Wall, G. Gorbsky, S. Tognin, P. Marchisio, M. Symons, D. Altieri (2002)
Regulation of microtubule stability and mitotic progression by survivin.Cancer research, 62 9
Lin Li, R. Thomas, Hidetaka Suzuki, J. Brabander, Xiaodong Wang, P. Harran (2004)
A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death.Science, 305 5689
Hong-Sug Kim, J. Lee, Y. Soung, W. Park, S. Kim, Jong Lee, J. Park, Yong Cho, Chang Kim, Seong-Whan Jeong, S. Nam, S. Kim, Jung Lee, N. Yoo, S. Lee (2003)
Inactivating mutations of caspase-8 gene in colorectal carcinomas.Gastroenterology, 125 3
Y. Soung, J. Lee, S. Kim, W. Park, S. Nam, Jung Lee, N. Yoo, S. Lee (2006)
Mutational analysis of proapoptotic caspase‐9 gene in common human carcinomasAPMIS, 114
T. Dohi, Elena Beltrami, N. Wall, J. Plescia, D. Altieri (2004)
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.The Journal of clinical investigation, 114 8
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. Peschon, M. Smyth (2002)
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1The Journal of Immunology, 168
S. Krajewski, A. Thor, S. Edgerton, D. Moore, M. Krajewska, John Reed (1997)
Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 2
B. Jansen, H. Schlagbauer‐Wadl, B. Brown, R. Bryan, A. Elsas, Markus Müller, K. Wolff, H. Eichler, H. Pehamberger (1998)
bcl-2 antisense therapy chemosensitizes human melanoma in SCID miceNature Medicine, 4
S. Hymowitz, M. O'connell, M. Ultsch, Amy Hurst, Klara Totpal, Avi Ashkenazi, Abraham Vos, Robert Kelley (2000)
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.Biochemistry, 39 4
M. Stephenson, P. Zamecnik (1978)
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.Proceedings of the National Academy of Sciences of the United States of America, 75 1
D. Green, H. Beere (2001)
Apoptosis: Mostly deadNature, 412
Mu-xiang Zhou, L. Gu, Fengzhi Li, Yerun Zhu, W. Woods, H. Findley (2002)
DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia CellsJournal of Pharmacology and Experimental Therapeutics, 303
A. Schimmer, A. Schimmer, Shadi Dalili, Shadi Dalili, R. Batey, S. Riedl (2006)
Targeting XIAP for the treatment of malignancyCell Death and Differentiation, 13
A. Nesterov, Malti Nikrad, T. Johnson, A. Kraft (2004)
Oncogenic Ras Sensitizes Normal Human Cells to Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand-Induced ApoptosisCancer Research, 64
S. Armeanu, U. Lauer, Irina Smirnow, M. Schenk, T. Weiss, M. Gregor, M. Bitzer (2003)
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.Cancer research, 63 10
(2001)
Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia
E. Cheng, B. Levine, L. Boise, C. Thompson, J. Hardwick (1996)
Bax-independent inhibition of apoptosis by Bcl-XLNature, 379
P. Secchiero, A. Gonelli, E. Carnevale, D. Milani, A. Pandolfi, D. Zella, G. Zauli (2003)
TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK PathwaysCirculation: Journal of the American Heart Association, 107
C. Scaffidi, S. Fulda, A. Srinivasan, C. Friesen, Feng Li, K. Tomaselli, K. Debatin, P. Krammer, M. Peter (1998)
Two CD95 (APO‐1/Fas) signaling pathwaysThe EMBO Journal, 17
K. Satoh, K. Kaneko, M. Hirota, A. Masamune, A. Satoh, T. Shimosegawa (2001)
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptor Expression and the Pathway of Apoptosis in Human Pancreatic CancerPancreas, 23
V. Cryns, Junying Yuan (1998)
Proteases to die for.Genes & development, 12 11
Shulin Wang, W. El-Deiry (2004)
The p53 pathway: targets for the development of novel cancer therapeutics.Cancer treatment and research, 119
K. Takeda, M. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, K. Okumura (2002)
Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor DevelopmentThe Journal of Experimental Medicine, 195
K. Rai, J. Moore, T. Boyd, L. Larratt, A. Golenkov, B. Koziner, A. Chanan-Khan, R. Bociek, L. Itri (2004)
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).Blood, 104
Hiromasa Sasaki, Y. Sheng, F. Kotsuji, B. Tsang (2000)
Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.Cancer research, 60 20
M. Ranson, C. Dive, T. Ward, J. Cummings, K. Connolly, S. Evans, L. Robson, J. Durkin, J. Jolivet, D. Jodrell (2006)
A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Q. Deveraux, E. Leo, H. Stennicke, K. Welsh, G. Salvesen, John Reed (1999)
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspasesThe EMBO Journal, 18
Ying Huang, Qin He, M. Hillman, R. Rong, M. Sheikh (2001)
Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.Cancer research, 61 18
Karthikeyan Kandasamy, S. Srinivasula, E. Alnemri, C. Thompson, S. Korsmeyer, J. Bryant, R. Srivastava (2003)
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.Cancer research, 63 7
S. Ray, Octavian Bucur, Alexandru Almasan (2005)
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitorApoptosis, 10
Xuefeng Huang, Tongyu Lin, Jian Gu, Lidong Zhang, J. Roth, L. Stephens, Y. Yu, Jinsong Liu, Bingliang Fang (2002)
Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograftGene Therapy, 9
R. Ravi, A. Bedi (2002)
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).Cancer research, 62 6
R. Klasa, M. Bally, R. Ng, J. Goldie, R. Gascoyne, F. Wong (2000)
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 6
Minji Jo, Tae-Hyoung Kim, D. Seol, J. Esplen, K. Dorko, T. Billiar, S. Strom (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligandNature Medicine, 6
D. McManus, C. Lefebvre, G. Cherton-Horvat, M. St-Jean, E. Kandimalla, S. Agrawal, S. Morris, J. Durkin, E. LaCasse (2004)
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeuticsOncogene, 23
Y. Soung, J. Lee, Hong-Sug Kim, W. Park, S. Kim, Jong Lee, J. Park, Y. Cho, Chang Kim, Yong-Gyu Park, S. Nam, Seong-Whan Jeong, S. Kim, Jung Lee, N. Yoo, S. Lee (2003)
Inactivating mutations of CASPASE-7 gene in human cancersOncogene, 22
G. Ambrosini, C. Adida, D. Altieri (1997)
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphomaNature Medicine, 3
M. Millward, A. Bedikian, R. Conry, M. Gore, H. Pehamberger, W. Sterry, A. Pavlick, R. Conti, D. Gordon, L. Itri (2004)
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
Lidong Zhang, B. Fang (2005)
Mechanisms of resistance to TRAIL-induced apoptosis in cancerCancer Gene Therapy, 12
J. Marshall, H. Chen, D. Yang, M. Figueira, K. Bouker, Y. Ling, M. Lippman, S. Frankel, D. Hayes (2004)
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 15 8
S. Kagawa, Chao He, J. Gu, P. Koch, S. Rha, J. Roth, S. Curley, L. Stephens, B. Fang (2001)
Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.Cancer research, 61 8
H. Olney, X. Weng, M. Watson, P. Beauparlant, D. Soulières, J. Viallet, M. Sarfati (2005)
Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015–070, in ex vivo chronic lymphoid leukemia (CLL) cellsJournal of Clinical Oncology, 23
A. Philchenkov, M. Zavelevich, T. Kroczak, M. Los (2004)
Caspases and cancer: mechanisms of inactivation and new treatment modalities.Experimental oncology, 26 2
J. Kirkwood, A. Bedikian, M. Millward, R. Conry, M. Gore, H. Pehamberger, W. Sterry, A. Pavlick, R. Deconti, L. Itri (2005)
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM)Journal of Clinical Oncology, 23
John Kerr, A. Wyllie, R. Alastair, Currie (1972)
Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue KineticsBritish Journal of Cancer, 26
V. Poulaki, C. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. Koutras, N. Mitsiades (2002)
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.The American journal of pathology, 161 2
U. Koenig, W. Sommergruber, S. Lippens (2005)
Aberrant expression of caspase-14 in epithelial tumors.Biochemical and biophysical research communications, 335 2
A. Chakravarti, E. Noll, P. Black, Daniel Finkelstein, D. Finkelstein, N. Dyson, J. Loeffler (2002)
Quantitatively determined survivin expression levels are of prognostic value in human gliomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 4
M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, J. Goldie (1999)
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 10
J. Fricker (1999)
On the TRAIL to a new cancer therapy.Molecular medicine today, 5 9
Xu Zhang, A. Franco, Kieda Myers, C. Gray, T. Nguyen, P. Hersey (1999)
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.Cancer research, 59 11
Haiying Sun, Z. Nikolovska-Coleska, Jianyong Chen, Chao-Yie Yang, Y. Tomita, Hongguang Pan, Yoshiko Yoshioka, K. Krajewski, P. Roller, Shaomeng Wang (2005)
Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics.Bioorganic & medicinal chemistry letters, 15 3
A. Bonni, A. Brunet, A. West, S. Datta, M. Takasu, M. Greenberg (1999)
Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.Science, 286 5443
R. Riccioni, L. Pasquini, G. Mariani, E. Saulle, A. Rossini, D. Diverio, E. Pelosi, A. Vitale, A. Chierichini, M. Cedrone, R. Foà, F. Coco, C. Peschle, U. Testa (2005)
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.Haematologica, 90 5
J. Tran, J. Rak, C. Sheehan, Samuel Saibil, E. LaCasse, R. Korneluk, R. Kerbel (1999)
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.Biochemical and biophysical research communications, 264 3
N. Mitsiades, V. Poulaki, C. Mitsiades, M. Tsokos (2001)
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.Cancer research, 61 6
T. Wu, K. Wagner, B. Bursulaya, P. Schultz, Q. Deveraux (2003)
Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction.Chemistry & biology, 10 8
L. Attardi, T. Jacks (1999)
The role of p53 in tumour suppression: lessons from mouse modelsCellular and Molecular Life Sciences CMLS, 55
D. James, J. Castro, O. Loria, C. Prada, R. Aguillon, T. Kipps (2006)
AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
S. Hsu, A. Kaipia, E. Mcgee, Michelle Lomeli, A. Hsueh (1997)
Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members.Proceedings of the National Academy of Sciences of the United States of America, 94 23
J. Houghton (1999)
Apoptosis and drug response.Current opinion in oncology, 11 6
A. Ashkenazi (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2
C. Ferreira, P. Valk, S. Span, Inge Ludwig, E. Smit, F. Kruyt, H. Pinedo, H. Tinteren, G. Giaccone (2001)
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 8
J. Jolivet, E. Dean, T. Ward, O. Denneny, C. Jacob, P. Goodege, C. Dive, M. Ranson (2006)
A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumoursJournal of Clinical Oncology, 26
C. Rudin, G. Otterson, A. Mauer, M. Villalona-Calero, R. Tomek, B. Prange, C. George, L. Szeto, E. Vokes (2002)
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 13 4
K. Schulze-Osthoff, D. Ferrari, M. Los, S. Wesselborg, M. Peter (1998)
Apoptosis signaling by death receptors.European journal of biochemistry, 254 3
A. Schimmer (2004)
Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical PracticeCancer Research, 64
Zhaoyu Jin, E. McDonald, D. Dicker, W. El-Deiry (2004)
Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis*Journal of Biological Chemistry, 279
Zhang Tao, T. Otevrel, Zhenqiang Gao, Zhiping Gao, S. Ehrlich, Jeremy Fields, B. Boman (2001)
Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer.Cancer research, 61 24
S. Crooke (1998)
Molecular mechanisms of antisense drugs: RNase H.Antisense & nucleic acid drug development, 8 2
Fengzhi Li, D. Altieri (1999)
Transcriptional analysis of human survivin gene expression.The Biochemical journal, 344 Pt 2
S. Kaufmann, D. Vaux (2003)
Alterations in the apoptotic machinery and their potential role in anticancer drug resistanceOncogene, 22
J. Castro, C. Prada, S. Kitada, D. Contreras, J. Viallet, John Reed, T. Kipps (2005)
GX15–070MS, a synthetic small molecule induces apoptosis in vitro and in vivo in chronic lymphocytic leukemiaJournal of Clinical Oncology, 23
M. Sanna, J. Correia, Odile Ducrey, Jongdae Lee, K. Nomoto, N. Schrantz, Q. Deveraux, R. Ulevitch (2002)
IAP Suppression of Apoptosis Involves Distinct Mechanisms: the TAK1/JNK1 Signaling Cascade and Caspase InhibitionMolecular and Cellular Biology, 22
R. Gianani, E. Jarboe, D. Orlicky, M. Frost, J. Bobak, Rainer Lehner, K. Shroyer (2001)
Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa.Human pathology, 32 1
Lydia Campos, Odile Sabido, J. Rouault, Denis Guvotat (1994)
Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells.Blood, 84 2
D. Lawrence, Z. Shahrokh, S. Marsters, Kirsten Achilles, Danny Shih, B. Mounho, K. Hillan, K. Totpal, L. Deforge, P. Schow, J. Hooley, S. Sherwood, R. Pai, Susan Leung, L. Khan, B. Gliniak, J. Bussiere, Craig Smith, S. Strom, S. Kelley, Judith Fox, Deborah Thomas, A. Ashkenazi (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsNature Medicine, 7
Q. Deveraux, H. Stennicke, G. Salvesen, John Reed (1999)
Endogenous Inhibitors of CaspasesJournal of Clinical Immunology, 19
P. Zamecnik, J. Goodchild, Y. Taguchi, P. Sarin (1986)
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.Proceedings of the National Academy of Sciences of the United States of America, 83 12
M. Andersen, Straten thor (2002)
Survivin--a universal tumor antigen.Histology and histopathology, 17 2
J. Rieger, U. Naumann, T. Glaser, A. Ashkenazi, M. Weller (1998)
APO2 ligand: a novel lethal weapon against malignant glioma?FEBS Letters, 427
H. Harlin, Stephanie Reffey, C. Duckett, T. Lindsten, C. Thompson (2001)
Characterization of XIAP-Deficient MiceMolecular and Cellular Biology, 21
Karthikeyan Kandasamy, R. Srivastava (2002)
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.Cancer research, 62 17
Shulin Wang, W. El-Deiry (2003)
TRAIL and apoptosis induction by TNF-family death receptorsOncogene, 22
Laleh Shayesteh, Yiling Lu, W. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G. Mills, J. Gray (1999)
PIK3CA is implicated as an oncogene in ovarian cancerNature Genetics, 21
A. Patnaik, H. Wakelee, M. Mita, A. Fitzgerald, M. Hill, N. Fox, T. Howard, S. Ullrich, A. Tolcher, B. Sikic (2006)
HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
Lin Chen, S. Willis, A. Wei, Brian Smith, J. Fletcher, M. Hinds, P. Colman, C. Day, Jerry Adams, D. Huang (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.Molecular cell, 17 3
S. Hymowitz, H. Christinger, G. Fuh, M. Ultsch, M. O'connell, R. Kelley, A. Ashkenazi, A. Vos (1999)
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.Molecular cell, 4 4
Daniel O'Connor, N. Wall, A. Porter, D. Altieri (2002)
A p34(cdc2) survival checkpoint in cancer.Cancer cell, 2 1
J. Lai, Wenzhi Tan, L. Benimetskaya, P. Miller, M. Colombini, C. Stein (2006)
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.Proceedings of the National Academy of Sciences of the United States of America, 103 19
A. Cristofano, P. Pandolfi (2000)
The Multiple Roles of PTEN in Tumor SuppressionCell, 100
M. Nagane, H. Huang, W. Cavenee (2001)
The potential of TRAIL for cancer chemotherapyApoptosis, 6
B. Fischer, D. Coelho, P. Dufour, J. Bergerat, J. Denis, J. Gueulette, P. Bischoff (2003)
Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis.Biochemical and biophysical research communications, 306 2
(2006)
implications of survivin expression in normal hematopoiesis
T. Griffith, R. Anderson, B. Davidson, Richard Williams, T. Ratliff (2000)
Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1The Journal of Immunology, 165
Chunying Du, M. Fang, Yucheng Li, Lily Li, Xiaodong Wang (2000)
Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP InhibitionCell, 102
G. Salvesen, C. Duckett (2002)
IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 3
D. Hockenbery, G. Núñez, C. Milliman, R. Schreiber, S. Korsmeyer (1990)
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 348
M. Müschen, M. Beckmann (2000)
CD95 ligand expression as a criterion of malignant transformation in breast cancerThe Journal of Pathology, 191
Q. Deveraux, John Reed (1999)
IAP family proteins--suppressors of apoptosis.Genes & development, 13 3
T. Oltersdorf, S. Elmore, A. Shoemaker, R. Armstrong, D. Augeri, B. Belli, M. Bruncko, T. Deckwerth, J. Dinges, P. Hajduk, M. Joseph, S. Kitada, S. Korsmeyer, Aaron Kunzer, A. Letai, Chi Li, M. Mitten, D. Nettesheim, S. Ng, Paul Nimmer, J. O'Connor, Anatol Oleksijew, A. Petros, John Reed, W. Shen, S. Tahir, C. Thompson, K. Tomaselli, Baole Wang, M. Wendt, Haichao Zhang, S. Fesik, S. Rosenberg (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 435
Heidi Leblanc, D. Lawrence, E. Varfolomeev, K. Totpal, J. Morlan, P. Schow, S. Fong, R. Schwall, D. Sinicropi, A. Ashkenazi (2002)
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog BaxNature Medicine, 8
Jerry Adams, S. Cory (2001)
Life-or-death decisions by the Bcl-2 protein family.Trends in biochemical sciences, 26 1
D. Antwerp, S. Martin, I. Verma, D. Green (1998)
Inhibition of TNF-induced apoptosis by NF-kappa B.Trends in cell biology, 8 3
N. Zaffaroni, M. Daidone (2002)
Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 5 2
C. Tepper, M. Seldin (1999)
Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma.Blood, 94 5
Q. Tong, Li-duan Zheng, Liang Wang, Fuqing Zeng, Fangmin Chen, Ji-hua Dong, Gong-cheng Lu (2005)
Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cellsCancer Gene Therapy, 12
(2005)
Phase I trial of AT-101, an orally bioavailable inhibitor of Bcl-2, in patients with advanced malignancies
L. Thomas, Ronald Johnson, John Reed, A. Thorburn (2004)
The C-terminal Tails of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas Receptors Have Opposing Functions in Fas-associated Death Domain (FADD) Recruitment and Can Regulate Agonist-specific Mechanisms of Receptor Activation*Journal of Biological Chemistry, 279
J. Bodmer, P. Meier, J. Tschopp, P. Schneider (2000)
Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL*The Journal of Biological Chemistry, 275
A. Tolcher, S. Antonia, L. Lewis, A. Mita, J. Mahany, N. Reddy, E. Till, D. Buell, A. Keating (2006)
A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
T. Oost, Chaohong Sun, R. Armstrong, A. Al-Assaad, S. Betz, T. Deckwerth, H. Ding, S. Elmore, R. Meadows, E. Olejniczak, A. Oleksijew, T. Oltersdorf, S. Rosenberg, A. Shoemaker, K. Tomaselli, Hua Zou, S. Fesik (2004)
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.Journal of medicinal chemistry, 47 18
A. Şanlioğlu, E. Dirice, Ç. Aydın, N. Erin, S. Koksoy, S. Sanlioglu (2005)
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cellsBMC Cancer, 5
M. Keane, S. Ettenberg, M. Nau, E. Russell, S. Lipkowitz (1999)
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.Cancer research, 59 3
T. Miyashita, John Reed (1992)
bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.Cancer research, 52 19
A. Nesterov, Xiaojun Lu, Michael Johnson, G. Miller, Y. Ivashchenko, A. Kraft (2001)
Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis*The Journal of Biological Chemistry, 276
Y. Hosomi, A. Gemma, Y. Hosoya, M. Nara, T. Okano, K. Takenaka, A. Yoshimura, K. Koizumi, K. Shimizu, S. Kudoh (2003)
Somatic mutation of the Caspase-5 gene in human lung cancer.International journal of molecular medicine, 12 4
Honglin Li, Hong Zhu, Chi-jie Xu, Junying Yuan (1998)
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of ApoptosisCell, 94
F. McCormick (2001)
Cancer gene therapy: fringe or cutting edge?Nature Reviews Cancer, 1
M. Sanna, C. Duckett, C. Duckett, B. Richter, C. Thompson, R. Ulevitch (1998)
Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP.Proceedings of the National Academy of Sciences of the United States of America, 95 11
R. Gascoyne, S. Adomat, S. Krajewski, M. Krajewska, D. Horsman, A. Tolcher, S. O'Reilly, P. Hoskins, A. Coldman, John Reed, J. Connors (1997)
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.Blood, 90 1
R. Harfouche, H. Hasséssian, Yang Guo, V. Faivre, C. Srikant, G. Yancopoulos, S. Hussain (2002)
Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells.Microvascular research, 64 1
I. Apakama, M. Robinson, N. Walter, R. Charlton, J. Royds, C. Fuller, D. Neal, F. Hamdy (1996)
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.British Journal of Cancer, 74
Y. Tsujimoto, L. Finger, J. Yunis, P. Nowell, C. Croce (1984)
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.Science, 226 4678
Konstantinos Drosopoulos, M. Roberts, L. Cermak, T. Sasazuki, S. Shirasawa, L. Andera, A. Pintzas (2005)
Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway*Journal of Biological Chemistry, 280
A. Ashkenazi, V. Dixit (1998)
Death receptors: signaling and modulation.Science, 281 5381
Xufeng Chen, H. Thakkar, F. Tyan, S. Gim, H. Robinson, Calvin Lee, S. Pandey, C. Nwokorie, N. Onwudiwe, R. Srivastava (2001)
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancerOncogene, 20
G. Ambrosini, C. Adida, G. Sirugo, D. Altieri (1998)
Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting*The Journal of Biological Chemistry, 273
Yigong Shi (2004)
Caspase activation, inhibition, and reactivation: A mechanistic viewProtein Science, 13
M. Walton, D. Whysong, P. O'Connor, D. Hockenbery, S. Korsmeyer, K. Kohn (1993)
Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.Cancer research, 53 8
C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Múgica, D. Altieri (1998)
Anti-apoptosis gene, survivin, and prognosis of neuroblastomaThe Lancet, 351
T. Chittenden, C. Flemington, Anne Houghton, R. Ebb, G. Gallo, B. Elangovan, G. Chinnadurai, R. Lutz (1995)
A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.The EMBO Journal, 14
Yibin Deng, Yahong Lin, Xiangwei Wu (2002)
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.Genes & development, 16 1
M. Nagane, Guohua Pan, Jessie Weddle, Vishva Dixit, W. Cavenee, H. Huang (2000)
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.Cancer research, 60 4
T. Dorai, Goluboff Et, C. Olsson, R. Buttyan (1997)
Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.Anticancer research, 17 5A
M. Mita, L. Ochoa, E. Rowinsky, J. Kuhn, G. Schwartz, L. Hammond, A. Patnaik, I. Yeh, E. Izbicka, K. Berg, A. Tolcher (2006)
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 17 2
S. O'brien, C. Cunningham, A. Golenkov, A. Turkina, S. Novick, K. Rai (2005)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
Jerry Adams, S. Cory (1998)
The Bcl-2 protein family: arbiters of cell survival.Science, 281 5381
A. Kelekar, C. Thompson (1998)
Bcl-2-family proteins: the role of the BH3 domain in apoptosis.Trends in cell biology, 8 8
H. Thakkar, Xufeng Chen, F. Tyan, S. Gim, H. Robinson, C. Lee, S. Pandey, C. Nwokorie, N. Onwudiwe, R. Srivastava (2002)
Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.The Journal of biological chemistry, 277 33
M. Hattori, H. Sakamoto, K. Satoh, T. Yamamoto (2001)
DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes.Cancer letters, 169 2
A. Ashkenazi, R. Pai, S. Fong, Susan Leung, David Lawrence, S. Marsters, Christine Blackie, Ling Chang, Amy McMurtrey, Andrea Hebert, L. Deforge, I. Koumenis, D. Lewis, Louise Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. Schwall (1999)
Safety and antitumor activity of recombinant soluble Apo2 ligand.The Journal of clinical investigation, 104 2
T. Teitz, T. Wei, Marcus Valentine, E. Vanin, J. Grenet, Virginia Valentine, F. Behm, A. Look, A. Look, J. Lahti, Vincent Kidd (2000)
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCNNature Medicine, 6
JC Reed (1998)
Bcl-2 family proteinsOncogene, 17
M. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, Ximena Opitz-Araya, R. Mccombie, J. Herman, W. Gerald, Y. Lazebnik, C. Cordon-Cardo, S. Lowe (2001)
Inactivation of the apoptosis effector Apaf-1 in malignant melanomaNature, 409
A. Suliman, A. Lam, R. Datta, R. Srivastava (2001)
Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathwaysOncogene, 20
G. Cox, J. Jones, A. Andi, K. Abrams, K. O'Byrne (2001)
Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.Lung cancer, 34 3
P. Secchiero, A. Gonelli, E. Carnevale, F. Corallini, C. Rizzardi, S. Zacchigna, M. Melato, G. Zauli (2004)
Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.Neoplasia, 6 4
S. Kaufmann, W. Earnshaw (2000)
Induction of apoptosis by cancer chemotherapy.Experimental cell research, 256 1
Q Wang, X Wang, A Hernandez, MR Hellmich, Z Gatalica, BM Evers (2002)
Regulation of TRAIL expression by the PI3-KINASE/Akt/GSK-3 pathway in human colon cancer cellsJ Biol Chem, 277
R. Yu, S. Mandlekar, S. Ruben, J. Ni, A. Kong (2000)
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.Cancer research, 60 9
S. Wiley, K. Schooley, P. Smolak, W. Din, Changwei Huang, J. Nicholl, G. Sutherland, T. Smith, C. Rauch, Craig Smith, R. Goodwin (1995)
Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity, 3 6
E. Affar, M. Germain, E. Winstall, M. Vodenicharov, R. Shah, G. Salvesen, G. Poirier (2001)
Caspase-3-mediated Processing of Poly(ADP-ribose) Glycohydrolase during Apoptosis*The Journal of Biological Chemistry, 276
A. Gross, J. McDonnell, S. Korsmeyer (1999)
BCL-2 family members and the mitochondria in apoptosis.Genes & development, 13 15
Mehdi Mesri, Manuel Morales-Ruiz, Elizabeth Ackermann, C. Bennett, Jordan Pober, W. Sessa, Dario Altieri (2001)
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting.The American journal of pathology, 158 5
T. Griffith, Wilson Chin, Glenn Jackson, D. Lynch, M. Kubin (1998)
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.Journal of immunology, 161 6
Y. Soung, J. Lee, S. Kim, W. Park, S. Nam, Jung Lee, N. Yoo, S. Lee (2004)
Somatic mutations of CASP3 gene in human cancersHuman Genetics, 115
M. Taniai, A. Grambihler, H. Higuchi, N. Werneburg, S. Bronk, Daniel Farrugia, S. Kaufmann, G. Gores (2004)
Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma CellsCancer Research, 64
I. Podgorski, Bonnie Sloane (2006)
Loss of caspase-8 in tumor cells: mechanism to overcome integrin-mediated death?Molecular interventions, 6 3
J. Qin, Vijaya Chaturvedi, B. Bonish, B. Nickoloff (2001)
Avoiding premature apoptosis of normal epidermal cellsNature Medicine, 7
A. Webb, D. Cunningham, F. Cotter, P. Clarke, F. Stefano, P. Ross, M. Corbo, Z. Dziewanowska (1997)
BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 349
A. Raffo, H. Perlman, Min‐Wei Chen, M. Day, Jack Streitman, R. Buttyan (1995)
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.Cancer research, 55 19
A. Tolcher, M. Mita, A. Patnaik, E. Rowinsky, A. Corey, M. Fleming, N. Fox, L. Weiner, N. Meropol, R. Cohen (2004)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumorsJournal of Clinical Oncology, 22
H. Kawasaki, D. Altieri, Cai Lu, M. Toyoda, T. Tenjo, N. Tanigawa (1998)
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.Cancer research, 58 22
H. Walczak, Robert Miller, K. Ariail, B. Gliniak, T. Griffith, M. Kubin, Wilson Chin, Jon Jones, A. Woodward, Tiep Le, Craig Smith, P. Smolak, R. Goodwin, C. Rauch, J. Schuh, D. Lynch (1999)
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 5
M. Krajewska, S. Krajewski, J. Epstein, A. Shabaik, J. Sauvageot, K. Song, S. Kitada, John Reed (1996)
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.The American journal of pathology, 148 5
A. Schimmer, K. Welsh, C. Pinilla, Zhiliang Wang, M. Krajewska, Marie-Josee Bonneau, Irene Pedersen, S. Kitada, F. Scott, B. Bailly-maitre, G. Glinsky, D. Scudiero, E. Sausville, G. Salvesen, A. Nefzi, J. Ostresh, R. Houghten, John Reed (2004)
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity.Cancer cell, 5 1
Y. Mizutani, M. Nakao, O. Ogawa, O. Yoshida, B. Bonavida, T. Miki (2001)
Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.The Journal of urology, 165 1
AA Kuang, GE Diehl, J Zhang, A Winoto (2000)
FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblastsJ Biol Chem, 275
X. Ling, Fengzhi Li (2004)
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology.BioTechniques, 36 3
Lin Li, R. Thomas, Hidetaka Suzuki, J. Brabander, Xiaodong Wang, P. Harran (2004)
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 305
T. Griffith, E. Broghammer (2001)
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.Molecular therapy : the journal of the American Society of Gene Therapy, 4 3
Honglin Zhou, Xin‐Ming Li, J. Meinkoth, R. Pittman (2000)
Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial LevelThe Journal of Cell Biology, 151
T. Fisher, A. Milner, Christopher Gregory, Ann Jackman, G. Aherne, John Hartley, C. Dive, John Hickman (1993)
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways.Cancer research, 53 14
J. Lai, L. Benimetskaya, A. Khvorova, Sijian Wu, Emily Hua, P. Miller, C. Stein (2005)
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.Molecular cancer therapeutics, 4 2
(2002)
TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo antitumor activity
Apoptosis, or programmed cell death, is essential for many physiological and pathological processes. Apoptosis results from an orderly activation of several cysteine proteases called caspases, which can be classically triggered by two upstream pathways: the intrinsic and extrinsic pathways. Deregulation of apoptosis is essential for tumor growth and a hallmark of cancer cells. In the recent years, many key elements of the apoptotic process have been identified and have become strategic targets for anticancer therapy. The novel approaches that target the apoptotic pathway may have either a direct proapoptotic effect or alternatively may sensitize cancer cells to other cytotoxics. This review describes the major elements of the apoptotic process, with a special focus of the tight interactions between the extrinsic and intrinsic pathways, and summarizes some of the most promising implications for cancer therapeutics.
Targeted Oncology – Springer Journals
Published: Oct 6, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.